<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.gmail-il
{mso-style-name:gmail-il;}
span.EmailStyle23
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>See below for an interesting webinar.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Another very interesting webinar<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Using a drug for Active surveillance that is mainly used for men with metastatic Prostate cancer.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>This will be of interest to all especially those on AS<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Regards<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>Phil Segal<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'>PCSToronto<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma",sans-serif'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma",sans-serif'> Howard Wolinsky [<a href="mailto:howard.wolinsky@gmail.com">mailto:howard.wolinsky@gmail.com</a>] <br><b>Sent:</b> May 25, 2021 10:10 AM<br><b>To:</b> Robert Allan; Philip Segal; Anthony Henry; Bill Manning; Thráinn Thorvaldsson; David King Keller, PhD<br><b>Subject:</b> Can you get the word out on the AnCan June 2 drop-in program (suggested by Phil Segal)<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><div><div><div><p class=MsoNormal><o:p> </o:p></p></div><div><div><p style='margin:0cm'><o:p> </o:p></p><p class=MsoNormal><img border=0 width=472 height=266 style='width:4.9166in;height:2.7708in' id="Picture_x0020_1" src="cid:image001.png@01D751AF.0D3B8490"><o:p></o:p></p><p style='margin:0cm'><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020;background:#FAFAFA'>The AnCan/UsToo speaker at 8 pm Eastern will be </span><span class=gmail-il><b><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020'>Michael</span></b></span><strong><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020'> </span></strong><span class=gmail-il><b><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020'>Schweizer</span></b></span><strong><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020'>, MD</span></strong><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020;background:#FAFAFA'>, a medical oncologist at the Seattle Cancer Care Alliance and the University of Washington in Seattle, who will discuss his research on the drug apalutamide (Erleada) in men on active surveillance. Apalutamide, a nonsteroidal antiandrogen medication, already is used to treat some men with advanced cancers.</span><o:p></o:p></p><p style='margin:0cm'><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020;background:#FAFAFA'><br>We will cover: Could apalutamide be for men on AS who are experiencing anxiety and thinking of dropping out? Or for whose new biopsies show greater volume? Who is the target for such medication? What does this drug do? What are the side effects? Cost?</span><o:p></o:p></p><p style='margin:0cm'><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020'><br><span style='background:#FAFAFA'>No registration is required, just drop into our regular meeting. </span></span><o:p></o:p></p><p style='margin:0cm'><strong><i><span style='font-family:"Arial",sans-serif;color:#666666;border:none windowtext 1.0pt;padding:0cm'>Go to Barniskis Room:</span></i></strong><span style='font-family:"Arial",sans-serif;color:#666666'> <span style='border:none windowtext 1.0pt;padding:0cm'><a href="https://www.gotomeet.me/AnswerCancer" target="_blank"><span style='color:#644389'>https://www.gotomeet.me/AnswerCancer</span></a></span></span><o:p></o:p></p><p style='margin:0cm'>For call in info go to: <a href="https://ancan.org/groups/joining-instructions/">https://ancan.org/groups/joining-instructions/</a><o:p></o:p></p><p class=MsoNormal align=center style='text-align:center'><o:p> </o:p></p><p class=MsoNormal><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020;background:#FAFAFA'>If you'd like to send questions ahead of time, please email Joe Gallo at </span><a href="mailto:joeg@ancan.org" target="_blank"><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#26ABE2;background:#FAFAFA'>joeg@ancan.org</span></a><span style='font-size:11.5pt;font-family:"Helvetica",sans-serif;color:#202020;background:#FAFAFA'> or you can also submit questions during the session.</span><o:p></o:p></p></div></div></div><div><div><div><div><div><p class=MsoNormal><o:p> </o:p></p></div></div></div></div></div></div></div></body></html>